Thursday, 9th February

Search
Speakers

2:10PM - 4:30PM

CSL Lecture Theatre

Chair: Richard Lock

Targeting BCL-2 family proteins to treat cancer: expanding the repertoire of small molecules BH3-mimetics - Guillaume Lessene
BCL2 antagonism in haematological malignancies: successes, pitfalls and potential - Andrew Roberts
Identification of oncogenic dependencies in acute myeloid leukaemia with mutations in isocitrate dehydrogenase - Lev Kats
Which pro-survival BCL-2 family member should be targeted for the treatment of which cancer? - Andreas Strasser
Tracking subclonal mutation frequencies throughout lymphoma development identifies cancer drivers in mouse models of lymphoma. - Anthony Uren

3:55PM - 4:30PM

Thursday, 9th February

Exhibition Hall

4:30PM - 6:15PM

Thursday, 9th February

CSL Lecture Theatre

Chair: David Vaux

The human cancer survival gene transcriptome. - Daniel Harari
Genetic editing of colonic organoids provides a molecularly distinct and orthotopic mouse model of serrated carcinogenesis. - Susan L Woods
The common ATM Ser49Cys variant is functionally defective for DNA damage response signalling - Caroline Atkinson
Targeted small molecule inhibitors (KATi) matched with a specific biomarker (Tip60 scoring) are promising new chemotherapeutic treatments for breast cancer. - James A.L. Brown
Oncogenic BRAF Mutation Induces Widespread DNA Hypermethylation in a Murine Model for Human Serrated Colorectal Neoplasia - Catherine Bond
CpG methylation accounts for genome-wide C>T mutation variation and cancer driver formation across different cancer types - Rebecca C. Poulos
The paracrine Hedgehog-FGF axis mediates cancer stem cell plasticity in triple negative breast cancers - Aurélie Cazet
Examining the effects of MAPK/ERK and CDK4 inhibition on the immune response to melanoma - Emily J Lelliott
Targeting chemoresistance within the hypoxic microenvironment of pancreatic cancer - James RW Conway
SVclone: inference of cancer cell fraction using structural variation - Marek Cmero
Tumor-initiating cells cannot form secondary tumors in the presence of an interleukin-1 mediated inflammatory response to the primary tumor - Christine L Chaffer
Targeting intestinal stem cells in cancer - Fred de Sauvage

6:15PM - 7:30PM

Thursday, 9th February

Seagrass Lawn

7:30PM - 10:00PM

Thursday, 9th February

Exhibition Hall

Establishing human colorectal cancer patient derived xenografts for pre-clinical drug trials - Suad Abdirahman
SMCHD1 regulates epithelial-to-mesenchymal transition in 5-FU drug resistant colorectal cancer cells - Nidhi Abraham
A fully-automated staining assay for probing the tumor microenvironment using fluorescent multiplex immunohistochemistry - Matias Abregu
Targeting PRMT5 in CDK2 driven resistance to CDK4 inhibitors in melanoma. - Shatha AbuHammad
Parp1-inhibitors Sensitizes Hyperthermia-Radiotherapy & Hyperthermia-Chemotherapy (CDDP) in Cervical Carcinoma Cells - Vidhula Ahire
Targeting copper homeostasis in glioblastoma using a chemically modified polyphenol - Aria M Ahmed-Cox
Describing the immune landscape across metastatic lesions - Ghamdan Al-Eryani
Parathyroid hormone 1 receptor (PTH1R) is a prognostic indicator in osteosarcoma: dog as a model - AWF A AL-KHAN
Response of melanoma cells to immune activity - Sara Alavi
CDK inhibition in combination with endocrine therapy to prevent the emergence of resistance in breast cancer - Sarah Alexandrou
STUDIES OF COLON CANCER STEM CELLS AND THEIR MARKERS - Reem ALHulais
Exploring the signal transducer and activator of transcription-3 (STAT3) as a therapeutic target in an in vivo gastric cancer model - Mariah Alorro
Targeting MDM4 to treat mutant p53 expressing Breast Cancer - Panimaya Jeffreena Miranda Alphonse Miranda
The effect of dietary intervention on DNA damage in breast cancer survivors - Amani Alshaikh
Cell penetrating phylomer peptides can successfully deliver the dominant-negative myc mutant omomyc and induce apoptosis in breast cancer cells - Mark Anastasas
Anti-metastasis therapy via nanoparticle mediated drug delivery - Stefan Bader
The epithelial-mesenchymal transition and immunoevasiveness in breast carcinoma - Aaron Bagnato
Aptamers as bio-recognition reagents for immunohistochemistry - Michelle Bauer
Immune escape in primary melanoma - Andreas Behren
Modelling oncogenic cooperation in mixed lineage leukaemia-rearranged acute myeloid leukaemia - Stefan Bjelosevic
Local inhibition of IGF-signaling in cancer by blockade of PAPPA - Marissa Blume
Determining the prognostic significance of circulating tumour cells in radiotherapy patients with non-small cell lung cancer through a clinical trial of treatment response evaluation by liquid biopsy - Benjamin J Blyth
Targeting tumour vascularisation to control breast cancer progression. - Claudine Bonder
Exosomes transfer chemotherapeutic drug resistance between colorectal cancer cells - Stephanie Boukouris
ROCK-education of cancer-associated fibroblasts in mammary tumours enhances their malignant phenotype and creates a tumour-permissive microenvironment - Sarah T Boyle
Antimalarial drug artesunate synergises with the BH3 mimetic drug ABT-737 to kill multiple myeloma cells in vitro - Margs S Brennan
MCL-1 inhibition combined with standard chemotherapy could be a safe strategy for cancer therapy - Kerstin Brinkmann
Elevated immune cell infiltration observed in high mammographic density breast tissue. - Kara L Britt
Sca-1 delineates an estrogen responsive stem/progenitor cell population within the mammary gland - Kara L Britt
Induction and therapeutic targeting of the PD-1/PD-L1 axis in breast cancer - Natasha K Brockwell
Analysis of chromosomal instability in 123 breast cancer samples through integrative proteogenomics - Diego Chacon
A new single-cell RNA sequencing workflow to investigate prostate tumour dormancy in the skeleton - Chia-Ling Chan
A genome-wide RNAi screen identifies novel regulators of AKT-induced senescence - Keefe T Chan
Putative neoantigens arising from frameshift mutations of Malignant Pleural Mesothelioma - Tian Mun Chee
Cells grown in 3D culture without scaffold support represent an improved in vitro model of malignant plural mesothelioma (MPM) - Yuen Yee Cheng
A strategy to protect against doxorubicin cardiotoxicity in a mouse model - Alison Cheong
Investigating the effect of combination therapy on cetuximab inhibition of epidermal growth factor receptor signalling in head and neck squamous cell carcinoma - Hui Yi Chew
Elucidating the role of androgen receptor in endocrine resistant ER+ breast cancer - Kee Ming Chia
Investigating the mutant allele variants of isocitrate dehydrogenase -1 and -2 in acute myeloid leukaemia - Ioana Chindris
Mysteries of Circulating Tumour Cells and Clusters in Prostate Cancer - A Review of Current and Potential Future Directions - Ken Chow
Characterising and modelling prostate cancer response to treatment - Michael Clarkson
Characterisation of copper homeostasis proteins in normal and cancerous prostate - Sharnel AS Clatworthy
Selective targeting of mutant p53 cancer cells by inhibition of system xCT- - Nick J Clemons
Genetic profiling of carcinomas of unknown primary (CUP) for the identification and characterisation of actionable and relevant targets - Britt Clynick
Yap regulates anabolic glucose metabolism to fuel premalignant growth - Andrew G Cox
ISDoT: In Situ Decellularisation of tissues for high resolution imaging and proteomic analysis of native extracellular matrix - Thomas R Cox
Mammary gland tissue resident macrophages in homeostasis and cancer - Caleb A Dawson
Derivation of a robust mouse mammary organoid system for studying tissue dynamics - Florijn Dekkers
Antibody profiling of colorectal cancer patients using a custom protein microarray platform - Jessica Duarte
Identification of a myoepithelial protein that suppresses the DCIS to invasive carcinoma transition in breast cancer - Hendrika M Duivenvoorden
Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature   - Kerryn Elliott
Targeted DNA Sequencing of Diagnostic Samples from the Nordic Mantle Cell Lymphoma trials, MCL2 and MCL3 - Christian Winther Eskelund
The ACRF Drug Discovery Centre: Assisting with early-stage drug discovery - Greg M Arndt
In vitro drug sensitivity testing of high risk childhood cancer patient cells for personalised drug treatments - Tim W Failes
Dissecting the functional significance of pigment heterogeneity in melanotic melanomas - Clare G Fedele
Elucidating the role of the androgen receptor in HER2-positive breast cancer - James Williams
Targeting Frizzled receptors in gastric cancer - Dustin Flanagan
Dual role of p120ctn in cancer: epithelial vs mesenchymal - Pamali Fonseka
The role of Interleukin-11 in pancreatic cancer progression - Ka Yee Fung
Acquired chemotherapeutic drug resistance in colorectal cancer is regulated by epithelial to mesenchymal transition and altered cellular pathways - Lahiru Gangoda
Vitamin D differentially regulates gene expression of heparanase in tumour cells - Shaun Gaskin
A network-based druggable genome analysis identifies novel therapeutic targets for non-WNT medulloblastoma - Laura A Genovesi
Defining functional drivers of oesophageal tumourigenesis - Jovana R Gotovac
Novel, highly selective small molecule inhibitor of Multidrug Resistance Protein 1 sensitises tumour cells to chemotherapy and radiotherapy - Kimberley M Hanssen
Engineering models of FGFR3-TACC3-driven respiratory cancers - Cassandra Harapas
Development of a national bioresource of patient derived xenografts (PDX) of primary and metastatic breast cancer, for the improvement of preclinical modeling and biomarker discovery - Kate Harvey
The Molecular Mechanisms Controlling Epithelial Cell Survival and Death in the Thymus During Cytoablative Treatment - Melanie Heinlein
The functionalization of a DNA chemical antibody targeting EpCAM for the delivery of a common chemotherapeutic agent - Justin Henri
XRAD SmART – a new instrument in Australia enabling image-guided radiotherapy in preclinical models of medulloblastoma - Hilary L Hii
Genetically Engineered Mouse Models of Proliferative High Grade Serous Ovarian Cancer - Gwo Yaw Ho
BET inhibitors engage the host immune system though direct repression of the immune checkpoint ligand PD-L1 - Simon J Hogg
The Role of Helix-loop-helix Transcription Factors in Mammary Gland Lineage Commitment - Holly Holliday
A distinct plasma lipid signature associated with poor prognosis in castrate-resistant prostate cancer - Lisa G Horvath
The role of IL-11 signalling in tumour development - Jennifer Huynh
Reducing platelet count extends survival and improves disease outcome in mouse models of metastatic lung cancer - Stephanie R Hyslop
Csk-binding protein controls red blood cell development via regulation of Lyn tyrosine kinase activity - Evan Ingley
shRNA screens indicate that DNA repair is the process critical for p53-mediated tumour suppression - Ana Janic
Investigating the role of heparanase in breast cancer progression using the PyMT-MMTV mouse model - Krish Jayatilleke
Combination treatment using MAPK and HDACi to enhance differentiation as a novel therapeutic strategy for colorectal cancer - Laura J Jenkins
Characterization of a novel isogenic xenograft model system reveals that FGF-13 is a driver of breast cancer metastasis - Cameron N Johnstone
RET-related microRNAs act as tumour suppressors in medullary thyroid carcinoma - Lauren Jin Suk Joo
Establishing a DNA barcoding approach to track how the immune system and immunotherapies regulate metastatic breast cancer growth at the clonal level - Simon Junankar
Dyspnea in the Patient with Pulmonary Metastases from Renal Cell Cancer during the Treatment with Nivolumab - Petra Jurcic
Extracellular vesicles containing mutant β-catenin activate Wnt signaling pathway in the tumor microenvironment - Hina Kalra
DNMT3A^R882H is essential for leukaemia maintenance in vivo - Madison J Kelly
Exploring the immunological landscape in locally advanced rectal cancer to improve neoadjuvant chemoradiotherapy followed by radical surgery - Joseph CH Kong
MicroRNA modulation of chemosensitivity in adrenocortical carcinoma - Grace Kwok
Regulator g protein signaling 5 controls pericyte phenotype switching and tumour blood vessel normalization - Devina D Lakhiani
Drug dose modulation on clonal dynamics: an in silico analysis - Luis Lara-Gonzalez
Investigating the role of mutant DNMT3A in the Development of Acute Myeloid Leukaemia - Erin M Lawrence
Assessing the Contribution of Interleukin-6 to Progression of Inflammatory Breast Cancer - Riley Morrow
A Homogenous Methyltransferase Enzymatic Assay Based on a Microbial Riboswitch - Alex Szabo
Combination drug therapies with the novel RNA polymerase I inhibitor CX-5461 improve efficacy in the treatment of multiple myeloma  - Kylee Maclachlan
Novel anti-tumour agents inhibit EGFR signalling in pancreatic cancer via their effects on the metastasis suppressor, NDRG1. - Zaklina Kovacevic

Friday →

Thursday, 9th February 29th Lorne Cancer Conference 2017

Session 1: Targeting Bcl2 family

Afternoon Tea

Session 2: FLASH talks and Cancer Stem Cells

Dinner

Poster Session I